Tenax Therapeutics, Inc.
TENX Nasdaq
SEC CIK 34956
Follow Tenax Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$16.7M
−5.7% vs same quarter last year
EPS, diluted
−$0.31
+22.5% vs same quarter last year
Operating cash flow
−$12.5M
−36.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$52.6M |
| FY24 | $0 | −$17.6M |
| FY23 | - | −$7.7M |
| FY22 | - | $11M |
| FY21 | - | −$32.5M |
| FY20 | - | −$9.9M |
| FY19 | - | −$8.4M |
| FY18 | - | −$14.1M |
| FY17 | - | −$8.8M |
| FY16 | $0 | −$43.9M |
| FY15 | $49.3K | −$14.1M |
| FY14 | $158.9K | −$19.5M |
| FY13 | $1.2M | −$9.4M |
| FY12 | $363.8K | −$15.7M |
| FY11 | $103.2K | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | 0% | −30062.8% | −28571.6% |
| FY14 | −65.5% | −10452.1% | −12296.2% |
| FY13 | 4.2% | −435.7% | −790.6% |
| FY12 | 13.5% | −2259.7% | −4319.2% |
| FY11 | 100% | 10238.4% | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$11.4M |
| FY21 | −$10.9M |
| FY20 | −$9.3M |
| FY19 | −$7.6M |
| FY18 | −$5.5M |
| FY17 | −$12.1M |
| FY16 | −$15.9M |
| FY15 | −$9.8M |
| FY14 | −$9.3M |
| FY13 | −$4.9M |
| FY12 | −$8.3M |
| FY11 | −$8.6M |
- Tenax Therapeutics
- Healthcare median
Show the numbers
| Year | Tenax Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | −28571.6% | −37.8% |
| FY14 | −12296.2% | −35.5% |
| FY13 | −790.6% | −37.1% |
| FY12 | −4319.2% | −29.1% |
| FY11 | - | −27.9% |